| Original language | English |
|---|---|
| Pages (from-to) | E613-E615 |
| Journal | EuroIntervention |
| Volume | 17 |
| Issue number | 8 |
| DOIs | |
| State | Published - Oct 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: EuroIntervention, Vol. 17, No. 8, 10.2021, p. E613-E615.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Early spontaneous reperfusion after acute myocardial infarction
T2 - True association with plaque phenotype or simple clinical observation?
AU - Joner, Michael
AU - Seguchi, Masaru
AU - Sato, Yu
AU - Virmani, Renu
N1 - Funding Information: M. Joner reports personal fees from OrbusNeich, AstraZeneca, and ReCor, grants and personal fees from Biotronik, Boston Scientific, and Edwards Lifesciences, and grant support from Amgen outside the submitted work. M. Joner has received funding from the German Center for Cardiovascular Research: DZHK (FKZ 81Z0600502; FKZ 81X2600526) and from the Leducq Foundation (grant agreement number 18CVD02). R. Virmani has received grant/research/ clinical trial support from NIH-HL141425, Leducq Foundation Grant, 4C Medical, 4Tech, Abbott Vascular, Ablative Solutions, Absorption Systems, Advanced NanoTherapies, Aerwave Medical, Alivas, Amgen, Asahi Medical, Aurios Medical, Avantec Vascular, BD, Biosensors, Biotronik, Biotyx Medical, Bolt Medical, Boston Scientific, Canon, Cardiac Implants, Cardiawave, CardioMech, Cardionomic, CeloNova, Cerus, EndoVascular, Chansu Vascular Technologies, Childrens National, Concept Medical, Cook Medical, Cooper Health, Cormaze, CRL, Croivalve, CSI, Dexcom, Edwards Lifesciences, Elucid Bioimaging, eLum Technologies, Emboline, Endotronix, Envision, Filterlex, Imperative Care, Innovalve, Innovative Cardiovascular Solutions, Intact Vascular, Interface Biologics, Intershunt Technologies, Invatin, Lahav, Limflow, L&J Bio, Lutonix, Lyra Therapeutics, Mayo Clinic, Maywell, MDS, MedAlliance, Medanex, Medtronic, Mercator, MicroPort, Microvention, Neovasc, Nephronyx, Nova Vascular, Nyra Medical, Occlutech, Olympus, Ohio Health, OrbusNeich, Ossio, Phenox, Pi-Cardia, Polares Medical, Polyvascular, Profusa, ProKidney, LLC, Protembis, Pulse Biosciences, Qool Therapeutics, Recombinetics, ReCor Medical, Regencor, Renata Medical, Restore Medical, Ripple Therapeutics, Rush University, Sanofi, Shockwave, SMT, SoundPipe, Spartan Micro, SpectraWAVE, Surmodics, Terumo Corporation, The Jacobs Institute, Transmural Systems, Transverse Medical, TruLeaf, UCSF, UPMC, Vascudyne, Vesper, Vetex Medical, Whiteswell, WL Gore, Xeltis. R. Virmani is a consultant for Abbott Vascular, Boston Scientific, CeloNova, OrbusNeich Medical, Terumo Corporation, W.L. Gore, Edwards Lifesciences, Cook Medical, CSI, ReCor Medical, Sino Medical Sciences Technology, Surmodics, and Bard BD, and is a scientific advisory board member for Medtronic and Xeltis. The other authors have no conflicts of interest to declare.
PY - 2021/10
Y1 - 2021/10
UR - http://www.scopus.com/inward/record.url?scp=85117557523&partnerID=8YFLogxK
U2 - 10.4244/EIJV17I8A110
DO - 10.4244/EIJV17I8A110
M3 - Review article
C2 - 34596565
AN - SCOPUS:85117557523
SN - 1774-024X
VL - 17
SP - E613-E615
JO - EuroIntervention
JF - EuroIntervention
IS - 8
ER -